{"id":648,"date":"2025-11-11T00:34:08","date_gmt":"2025-11-11T08:34:08","guid":{"rendered":"https:\/\/getasecondopinion.ai\/blog\/?p=648"},"modified":"2025-11-11T00:34:09","modified_gmt":"2025-11-11T08:34:09","slug":"fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/","title":{"rendered":"Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection"},"content":{"rendered":"\n<p>Fresenius Kabi has issued a voluntary nationwide recall of three lots of Famotidine Injection USP, 20 mg per 2 mL (10 mg\/mL), after laboratory testing identified an out\u2011of\u2011specification impurity result in a single lot. The recall is precautionary and intended to protect patients and maintain supply-chain integrity while further investigations continue.<sup>1<\/sup> <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Summary of the recall<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Product recalled: Famotidine Injection USP, 20 mg per 2 mL (10 mg\/mL), single\u2011dose vial.<\/li>\n\n\n\n<li>Scope: Voluntary nationwide recall of three lots distributed in the United States.<sup>1<\/sup> <\/li>\n\n\n\n<li>Reason: An out\u2011of\u2011specification impurity detected during stability or release testing; additional lots were included as a precautionary measure while the root cause is investigated.<sup>1<\/sup> <\/li>\n\n\n\n<li>Patient risk: No adverse events tied to the impurity have been publicly reported in the FDA notice; recall is preventative.<sup>1<\/sup> <\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Regulatory and manufacturer statements<\/h3>\n\n\n\n<p>Fresenius Kabi coordinated the recall with the U.S. Food and Drug Administration (FDA). The FDA\u2019s safety communication describes the recall details, identifies the affected product, and confirms that the recall arose from impurity testing results rather than confirmed clinical harm.<sup>1<\/sup>  Fresenius Kabi\u2019s recall communication requests that customers check inventories, quarantine affected lots, and follow the company\u2019s return procedures.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Clinical and safety considerations<\/h3>\n\n\n\n<p>Famotidine is an H2\u2011receptor antagonist commonly used for stress ulcer prophylaxis, gastric acid suppression, and adjunctive therapy in certain gastroesophageal conditions. When a parenteral product undergoes recall for impurity concerns, institutions should:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li>Immediately remove and quarantine the affected lot numbers from clinical areas, automated dispensing cabinets (ADCs), and pharmacies.<sup>1<\/sup> <\/li>\n\n\n\n<li>Suspend administration of suspect vials until lot verification and alternative supply are confirmed.<\/li>\n\n\n\n<li>Notify treating teams and update electronic medication administration records and order sets to prevent inadvertent selection of quarantined lots.<\/li>\n\n\n\n<li>Monitor patients who recently received the product for unexpected adverse effects, document any findings, and report events through institutional safety channels and to the manufacturer and FDA as appropriate.<sup>1<\/sup> <\/li>\n<\/ol>\n\n\n\n<p>No change to standard monitoring beyond routine post\u2011infusion observation is recommended unless clinical signs suggest a reaction potentially linked to the product.<\/p>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-global-padding is-layout-constrained wp-container-core-group-is-layout-675f737c wp-block-group-is-layout-constrained\" style=\"padding-right:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-group cta-background has-background has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-64f51f8a wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-radius:30px;background-color:#fff6eb;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30);box-shadow:var(--wp--preset--shadow--natural);background-image:url(&apos;https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/10\/cta-background-02.webp&apos;);background-position:100% 100%;background-repeat:no-repeat;background-size:contain;background-attachment:scroll;\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-9d2deb30 wp-block-group-is-layout-constrained\" style=\"padding-top:0px;padding-right:0px;padding-bottom:10px\">\n<h3 class=\"wp-block-heading has-text-align-center has-accent-1-color has-text-color has-link-color has-large-font-size wp-elements-e1a2b4d20c009cbe1ac01729b645a8a1\">Experiencing Side Effects? <br>Let\u2019s Rethink Your Meds.<\/h3>\n\n\n\n<p>Explore treatment options that may work better for your body &#8211; with fewer side effects and lower costs. It\u2019s fast, free, and tailored to you. <strong><a href=\"https:\/\/getasecondopinion.ai\/intro-summary\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Inventory management and substitution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Triage current on\u2011hand stock by lot number and expiration date; segregate recalled lots and mark them clearly for return or disposal per manufacturer instructions.<sup>1<\/sup> <\/li>\n\n\n\n<li>Consider validated therapeutic alternatives for IV acid suppression (e.g., intravenous proton\u2011pump inhibitors) where clinically appropriate, taking into account indication, renal function, drug interactions, and formulary status.<\/li>\n\n\n\n<li>Update procurement teams to communicate demand forecasts and preempt shortages; work with wholesalers and the manufacturer for replacement product where available.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Communication and documentation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Maintain a clear audit trail: record lot numbers, quantities quarantined, patient exposures (if any), and communications with Fresenius Kabi and the FDA.<\/li>\n\n\n\n<li>Inform frontline clinicians, nursing leadership, and pharmacy staff via email and intranet notices with explicit guidance on identification and handling of recalled lots.<\/li>\n\n\n\n<li>Share documentation with quality\/safety committees and include the recall in periodic medication\u2011safety reports.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Practical checklist for hospitals and pharmacies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Verify lot numbers against the FDA notice and manufacturer recall letter; isolate any matches.<sup>1<\/sup> <\/li>\n\n\n\n<li>Stop dispensing or administering matched lots; secure them in a quarantine area labeled \u201cRecalled\u2014Do Not Use.\u201d<\/li>\n\n\n\n<li>Follow manufacturer return instructions and regulatory reporting requirements.<\/li>\n\n\n\n<li>Use clinical judgment for patients recently dosed; escalate any unexpected clinical events to pharmacovigilance.<\/li>\n<\/ul>\n\n\n\n<p>This voluntary recall is a precautionary action initiated after laboratory detection of an out\u2011of\u2011specification impurity in one lot, with two additional lots included while investigations proceed.<sup>1<\/sup>  There is no public evidence of patient harm linked to these lots, but strict inventory control, timely communication, and documentation are essential to maintain patient safety and therapeutic continuity.<\/p>\n\n\n\n<p>Recalled Lots:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th><u>Product Name\/Size<\/u>\u00a0<\/th><th><u>Unit of Use NDC Number<\/u>\u00a0<\/th><th><u>Unit of Sale NDC Number<\/u>\u00a0<\/th><th><u>Product Code<\/u>\u00a0<\/th><th><u>Batch Number<\/u>\u00a0<\/th><th><u>Expiration<\/u>\u00a0<br><u>Date<\/u>\u00a0<\/th><th><u>First Ship<\/u>\u00a0<u>Date<\/u>\u00a0<\/th><th><u>Last Ship<\/u>\u00a0<u>Date<\/u>\u00a0<\/th><\/tr><\/thead><tbody><tr><td rowspan=\"3\">Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2mL fill in a 2 mL vial\u00a0<\/td><td rowspan=\"3\">63323-739-11\u00a0<\/td><td rowspan=\"3\">63323-739-12\u00a0<\/td><td rowspan=\"3\">730912\u00a0\u00a0<\/td><td>6133156<\/td><td>08\/2026\u00a0<\/td><td>01\/02\/2025\u00a0<\/td><td>02\/11\/2025\u00a0<\/td><\/tr><tr><td>6133194\u00a0<\/td><td>08\/2026\u00a0<\/td><td>02\/04\/2025\u00a0<\/td><td>04\/11\/2025\u00a0<\/td><\/tr><tr><td>6133388\u00a0<\/td><td>10\/2026\u00a0<\/td><td>05\/23\/2025\u00a0<\/td><td>05\/23\/2025\u00a0<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"402\" src=\"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-label-recall.jpg\" alt=\"\" class=\"wp-image-649\" srcset=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-label-recall.jpg 1020w, https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-label-recall-300x118.jpg 300w, https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-label-recall-768x303.jpg 768w\" sizes=\"auto, (max-width: 1020px) 100vw, 1020px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"418\" src=\"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-label-recall-2.jpg\" alt=\"\" class=\"wp-image-650\" srcset=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-label-recall-2.jpg 1020w, https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-label-recall-2-300x123.jpg 300w, https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-label-recall-2-768x315.jpg 768w\" sizes=\"auto, (max-width: 1020px) 100vw, 1020px\" \/><\/figure>\n\n\n\n<p>Consumers with questions regarding this recall can contact Fresenius Kabi USA Quality Assurance at 1-866-716-2459, Monday through Friday, during the hours of 8:00 a.m. to 5:00 p.m. Central Standard Time. Patients should contact their physician or health care provider if they have experienced any problems that may be related to receiving this drug product.<\/p>\n\n\n\n<p>Adverse reactions or quality problems experienced with the use of this product may be reported to Fresenius Kabi Medical Affairs or Vigilance departments at 1-800-551-7176, Monday through Friday, during the hours of 8:00 a.m. to 5:00 p.m. Central Standard Time, or send an e-mail to either&nbsp;<a href=\"mailto:productcomplaint.USA@fresenius-kabi.com\">productcomplaint.USA@fresenius-kabi.com<\/a>&nbsp;or&nbsp;<a href=\"mailto:adverse.events.USA@fresenius-kabi.com\">adverse.events.USA@fresenius-kabi.com<\/a>.<\/p>\n\n\n\n<p>Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA&#8217;s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Complete and submit the report Online:\u00a0<a href=\"https:\/\/www.fda.gov\/medwatch\/report.htm\">www.fda.gov\/medwatch\/report.htm<\/a><\/li>\n\n\n\n<li>Regular Mail or Fax: Download form\u00a0<a href=\"https:\/\/www.fda.gov\/MedWatch\/getforms.htm\">www.fda.gov\/MedWatch\/getforms.htm<\/a>\u00a0or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.<\/li>\n<\/ul>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-global-padding is-layout-constrained wp-container-core-group-is-layout-675f737c wp-block-group-is-layout-constrained\" style=\"padding-right:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-group cta-background has-custom-off-white-background-color has-background has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-64f51f8a wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-radius:30px;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30);box-shadow:var(--wp--preset--shadow--natural);background-image:url(&apos;https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/cta-background-01.webp&apos;);background-position:100% 100%;background-repeat:no-repeat;background-size:contain;background-attachment:scroll;\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-153751c2 wp-block-group-is-layout-constrained\" style=\"padding-bottom:10px\">\n<h3 class=\"wp-block-heading has-text-align-center has-accent-1-color has-text-color has-link-color has-large-font-size wp-elements-b6fe6b9c1e90c3ca0e3d22a4a0e21d9e\">Better Treatment, Lower Cost &#8211; No Catch.<\/h3>\n\n\n\n<p>Find safer, more effective medications with fewer side effects &#8211; often for less money. It\u2019s fast, free, and personalized. <strong><a href=\"https:\/\/getasecondopinion.ai\/intro-summary\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<p><strong>Reference<\/strong><\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li>U.S. Food and Drug Administration. \u201cFresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP 20 mg\/2 mL (10 mg\/mL).\u201d FDA Safety Alerts. <a href=\"https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/fresenius-kabi-issues-voluntary-nationwide-recall-three-lots-famotidine-injection-usp-20-mg-2-ml-10#:~:text=The%20product%20is%20being%20recalled%20due%20to%20out-of-specification,included%20in%20the%20recall%20as%20a%20precautionary%20measure.\">https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/fresenius-kabi-issues-voluntary-nationwide-recall-three-lots-famotidine-injection-usp-20-mg-2-ml-10.<\/a><\/li>\n<\/ol>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fresenius Kabi has issued a voluntary nationwide recall of three lots of Famotidine Injection USP, 20 mg per 2 mL (10 mg\/mL), after laboratory testing identified an out\u2011of\u2011specification impurity result in a single lot. The recall is precautionary and intended to protect patients and maintain supply-chain integrity while further investigations continue.1 Summary of the recall [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":653,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40],"tags":[352,353,351,354,347,350,349,262,355,348],"class_list":["post-648","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fda-updates","tag-drug-safety-alert","tag-famotidine-injection-recall","tag-famotidine-usp-recall","tag-fda-drug-recall","tag-fresenius-kabi-recall","tag-hospital-pharmacy-recall","tag-injectable-famotidine","tag-medication-safety","tag-pharma-supply-chain","tag-pharmaceutical-recall-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection - Get a Second Opinion<\/title>\n<meta name=\"description\" content=\"Fresenius Kabi famotidine injection recall: voluntary recall of three lots for impurity; guidance for clinicians and pharmacies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection - Get a Second Opinion\" \/>\n<meta property=\"og:description\" content=\"Fresenius Kabi famotidine injection recall: voluntary recall of three lots for impurity; guidance for clinicians and pharmacies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/\" \/>\n<meta property=\"og:site_name\" content=\"Get a Second Opinion\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/getasecondopinion\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T08:34:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-11T08:34:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-Recall.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"G2O\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G2O\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/\"},\"author\":{\"name\":\"G2O\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\"},\"headline\":\"Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection\",\"datePublished\":\"2025-11-11T08:34:08+00:00\",\"dateModified\":\"2025-11-11T08:34:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/\"},\"wordCount\":882,\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Famotidine-Recall.jpg\",\"keywords\":[\"drug safety alert\",\"Famotidine injection recall\",\"famotidine USP recall\",\"FDA drug recall\",\"Fresenius Kabi recall\",\"hospital pharmacy recall\",\"injectable famotidine\",\"medication safety\",\"pharma supply chain\",\"pharmaceutical recall news\"],\"articleSection\":[\"FDA Updates\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/\",\"name\":\"Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection - Get a Second Opinion\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Famotidine-Recall.jpg\",\"datePublished\":\"2025-11-11T08:34:08+00:00\",\"dateModified\":\"2025-11-11T08:34:09+00:00\",\"description\":\"Fresenius Kabi famotidine injection recall: voluntary recall of three lots for impurity; guidance for clinicians and pharmacies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Famotidine-Recall.jpg\",\"contentUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Famotidine-Recall.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Photograph of a gloved hand holding a clear 2 mL vial with a gray rubber stopper and silver crimp, set against a softly blurred background of teal and blue medical vials and supplies; a wide semi\u2011transparent teal banner across the image contains bold white headline text reading \u201cFresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection,\u201d with the banner positioned so no vial or hand obscures the text.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Insights\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Policy Alerts\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/policy-alerts\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FDA Updates\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/policy-alerts\\\/fda-updates\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"name\":\"Get a Second Opinion\",\"description\":\"Insights\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\",\"name\":\"Get a Second Opinion\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"contentUrl\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"width\":1000,\"height\":129,\"caption\":\"Get a Second Opinion\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/getasecondopinion\",\"https:\\\/\\\/www.instagram.com\\\/getasecondopinion\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\",\"name\":\"G2O\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"caption\":\"G2O\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection - Get a Second Opinion","description":"Fresenius Kabi famotidine injection recall: voluntary recall of three lots for impurity; guidance for clinicians and pharmacies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/","og_locale":"en_US","og_type":"article","og_title":"Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection - Get a Second Opinion","og_description":"Fresenius Kabi famotidine injection recall: voluntary recall of three lots for impurity; guidance for clinicians and pharmacies.","og_url":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/","og_site_name":"Get a Second Opinion","article_publisher":"https:\/\/www.facebook.com\/getasecondopinion","article_published_time":"2025-11-11T08:34:08+00:00","article_modified_time":"2025-11-11T08:34:09+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-Recall.jpg","type":"image\/jpeg"}],"author":"G2O","twitter_card":"summary_large_image","twitter_misc":{"Written by":"G2O","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/#article","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/"},"author":{"name":"G2O","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20"},"headline":"Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection","datePublished":"2025-11-11T08:34:08+00:00","dateModified":"2025-11-11T08:34:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/"},"wordCount":882,"publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-Recall.jpg","keywords":["drug safety alert","Famotidine injection recall","famotidine USP recall","FDA drug recall","Fresenius Kabi recall","hospital pharmacy recall","injectable famotidine","medication safety","pharma supply chain","pharmaceutical recall news"],"articleSection":["FDA Updates"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/","url":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/","name":"Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection - Get a Second Opinion","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/#primaryimage"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-Recall.jpg","datePublished":"2025-11-11T08:34:08+00:00","dateModified":"2025-11-11T08:34:09+00:00","description":"Fresenius Kabi famotidine injection recall: voluntary recall of three lots for impurity; guidance for clinicians and pharmacies.","breadcrumb":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/#primaryimage","url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-Recall.jpg","contentUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/Famotidine-Recall.jpg","width":1536,"height":1024,"caption":"Photograph of a gloved hand holding a clear 2 mL vial with a gray rubber stopper and silver crimp, set against a softly blurred background of teal and blue medical vials and supplies; a wide semi\u2011transparent teal banner across the image contains bold white headline text reading \u201cFresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection,\u201d with the banner positioned so no vial or hand obscures the text."},{"@type":"BreadcrumbList","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fresenius-kabi-issues-voluntary-nationwide-recall-of-three-lots-of-famotidine-injection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Insights","item":"https:\/\/www.getasecondopinion.ai\/blog\/"},{"@type":"ListItem","position":2,"name":"Policy Alerts","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/policy-alerts\/"},{"@type":"ListItem","position":3,"name":"FDA Updates","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/policy-alerts\/fda-updates\/"},{"@type":"ListItem","position":4,"name":"Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection"}]},{"@type":"WebSite","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website","url":"https:\/\/www.getasecondopinion.ai\/blog\/","name":"Get a Second Opinion","description":"Insights","publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.getasecondopinion.ai\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization","name":"Get a Second Opinion","url":"https:\/\/www.getasecondopinion.ai\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","contentUrl":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","width":1000,"height":129,"caption":"Get a Second Opinion"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/getasecondopinion","https:\/\/www.instagram.com\/getasecondopinion"]},{"@type":"Person","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20","name":"G2O","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","caption":"G2O"}}]}},"_links":{"self":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/comments?post=648"}],"version-history":[{"count":3,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/648\/revisions"}],"predecessor-version":[{"id":654,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/648\/revisions\/654"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media\/653"}],"wp:attachment":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media?parent=648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/categories?post=648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/tags?post=648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}